Scott M Dehm

Faculty, Professor

University of Minnesota
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (56)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Purpose: Androgen receptor pathway inhibitors (ARPI), such as enzalutamide and abiraterone, are standard treatments for metastatic castration-resistant prostate cancer (mCRPC). However, a subset of patients display primary resistance and most eventually acquire secondary resistance. This study aimed to define genomic features of ARPI resistance using longitudinal ctDNA analysis. Experimental Design: We used the targeted AR-ctDETECT cell-free DNA (cfDNA) sequencing assay to profile tumor-derived genomic alterations in plasma samples collected at baseline and progression from patients with mCRPC enrolled in the phase III Alliance A031201 trial of first-line enzalutamide with or without abiraterone. Analysis focused on 327 patients with paired samples available from both time points. Results: Progression plasma samples displayed elevated cfDNA levels and increased ctDNA positivity. AR was the most frequently altered gene at baseline and at progression. AR copy-number gains and AR genomic structural rearrangements (AR-GSR) increased at progression, along with copy-number losses of FANCA, POLD1, RAD54L, CDKN2A, ZNRF3, and ETS2. An AR extrachromosomal DNA signature was enriched at progression and was associated with AR-GSRs predicted to truncate the AR ligand-binding domain. Stratification by two extremes of radiographic progression-free survival revealed preferential accumulation of AR alterations in patients with delayed progression and a higher burden of non-AR alterations in patients with rapid progression. Conclusions: AR alterations in ctDNA accumulate at progression in patients with mCRPC treated with ARPIs, especially in those with initially durable responses. These findings support the use of liquid biopsy to serially track resistance mechanisms and inform precision therapy in advanced prostate cancer.

Year:

2026

Year:

2026

Year:

2026

Purpose: Germline alterations in homologous recombination repair (gHRR) genes affect the pathogenesis, treatment options, and survival of patients with cancer. However, distinct gHRR gene alterations may differentially affect treatment response and oncogenic signaling. In this study, we interrogated genomic and transcriptomic data and assessed clinical outcomes of patients with gHRR mutations across four BRCA-associated cancers (breast, ovarian, pancreatic, and prostate cancers) to identify therapeutic vulnerabilities. Experimental Design: We assessed 24,309 patients undergoing matched tumor/normal next-generation DNA and RNA sequencing. Annotated gHRR gene variants [germline BRCA1, germline BRCA2, germline PALB2, germline ATM (gATM), and germline CHEK2] were analyzed. HRs were used to assess survival outcomes comparing germline versus sporadic groups. Somatic alterations and their frequencies were compared across gHRR-altered groups. Differential gene expression and gene set enrichment analysis were used to compare transcriptomic profiles. Results: Somatic TP53 mutations were depleted in gATM carriers (P < 0.05) across all four BRCA-associated cancers by up to 2.5-fold. Tumors with germline BRCA1/2 mutations were associated with improved survival in patients with ovarian cancer and had consistent enrichment of TP53 mutations in all four cancers. gATM mutations displayed elevated p53 transcriptional activity in all four cancers, with significance reached in breast and prostate cancers (P < 0.01). In breast, ovarian, and prostate cancers, gATM tumors demonstrated significantly increased inflammatory pathways (P < 0.001). Finally, using gene dependency data, we found that cell lines that were highly dependent on ATM were co-dependent on canonical p53 function. Conclusions: gATM-associated cancers seem to require intact p53 activity and this synthetic essentiality may be used to guide targeted therapies that perturb canonical TP53 function.

Year:

2025

The roles of nucleoplasm-residing nucleoporins (NUP) in solid tumors, including prostate cancer, remain unknown. In this study, we reveal the clinical significance and mechanistic role of the off-pore NUP, soluble POM121 (sPOM121), as a crucial transcriptional regulator that enhances the aggressiveness of metastatic prostate cancer. Using orthogonal methodologies in human samples, sPOM121 was identified as the predominantly expressed nucleoplasmic NUP in prostate cancer. Unbiased proteomic and epigenomic studies demonstrate that sPOM121, through its C-terminus, interacts with the chromatin remodeler SMARCA5 at gene promoter sites and localizes at nuclear condensates, reprogramming gene expression. Indeed, sPOM121 regulates a distinct oncogenic gene network, including β-catenin, leading to prostate cancer progression and immune evasion. Importantly, targeting the sPOM121/β-catenin axis in patient-derived preclinical and syngeneic mouse models halts prostate cancer aggressiveness and enhances antitumor immunity. Taken together, these findings reveal previously unknown actionable reprogramming functions of off-pore NUPs in solid tumors. Significance: This study uncovers how oncogenic signaling programs are transcriptionally heightened by the NUP sPOM121 in metastatic prostate cancer. Localization of sPOM121 at active transcriptional nuclear condensates propels disease progression and immune evasion, offering novel anticancer therapeutic opportunities.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (71)

Alexander Tsai

Assistant Professor

University of Minnesota

UNITED STATES
View details

Qingshu Meng

Research Assistant Professor

Northwestern University Feinberg School of Medicine

UNITED STATES
View details

Yvette Soignier

University of Minnesota Twin Cities

UNITED STATES
View details

Weibo Cai

University of Wisconsin-Madison

UNITED STATES
View details

Andrew Armstrong

Professor

Duke Cancer Institute

UNITED STATES
View details

Oliver Sartor

Tulane University School of Medicine

UNITED STATES
View details

Laura Kotz

University of Minnesota Twin Cities

UNITED STATES
View details

John Lozada

University of Rochester Medical Center

UNITED STATES
View details

George Sledge

-

UNITED STATES
View details

Grace Blitzer

University of Wisconsin-Madison

UNITED STATES
View details

Philippa Kennedy

Faculty, Assistant Professor

University of Minnesota

UNITED STATES
View details

Joshua Lang

Professor

University of Wisconsin-Madison

UNITED STATES
View details

Natalie Reizine

Assistant Professor

University of Chicago

UNITED STATES
View details

Luke Selth

Associate Professor in Medical Sciences

Flinders University

AUSTRALIA
View details

Geraldine Laven-Law

Flinders University

AUSTRALIA
View details

Jason M. Sheltzer

Stanford University

UNITED STATES
View details

Scott Tagawa

Weill Cornell Medicine

UNITED STATES
View details

Emil Lou

University of Minnesota

UNITED STATES
View details

Ari VanderWalde

Global Head of Clinical Trials

-

UNITED STATES
View details

Dang Nguyen

Faculty, Assistant Professor

University of Minnesota

UNITED STATES
View details

Eugene Shenderov

Associate Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

HAMID EMAMEKHOO

University of Wisconsin-Madison

UNITED STATES
View details

Rendong Yang

Associate Professor

Northwestern University Feinberg School of Medicine

UNITED STATES
View details

Haojie Huang

Professor

Mayo Clinic College of Medicine and Science

UNITED STATES
View details

Steven Kregel

Assistant Professor

Loyola University Chicago

UNITED STATES
View details

Justin Hwang

Associate Professor

University of Minnesota

UNITED STATES
View details

Shuang G. Zhao

University of Wisconsin-Madison

UNITED STATES
View details

Liguo Wang

Professor of Biomedical Informatics

Mayo Clinic Minnesota

UNITED STATES
View details

Bin Luo

Assistant Professor

Kennesaw State University

UNITED STATES
View details

Siddhartha Yadav

Associate Professor of Oncology

Mayo Clinic

UNITED STATES
View details

Veronica Rodriguez-Bravo

Associate Professor

Mayo Clinic

UNITED STATES
View details

Shijia Zhu

Assistant Professor

University of Minnesota

UNITED STATES
View details

Catherine Marshall

Associate Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Rohan Garje

Clinical Associate professor

Iowa State University

UNITED STATES
View details

Luke Gaughan

Reader in Molecular Oncology

Newcastle University

UNITED KINGDOM
View details

Elisabeth I. Heath

Wayne State University School of Medicine

UNITED STATES
View details

Raj Kumar Shrestha

Research Associate

Flinders University

AUSTRALIA
View details

Susan Halabi

Duke University

UNITED STATES
View details

David Kosoff

University of Wisconsin-Madison

UNITED STATES
View details

Josep Domingo-Domenech

Professor

Mayo Clinic

UNITED STATES
View details

Jonathan W Engle

Associate Professor

University of Wisconsin-Madison

UNITED STATES
View details

Menggang Yu

Professor

University of Michigan

UNITED STATES
View details

Haidong Dong

Professor/Consultant

Mayo Clinic Rochester

UNITED STATES
View details

Jacob Orme

Assistant Professor

Mayo Clinic

UNITED STATES
View details

Martin Felices

Associate Professor

University of Minnesota

UNITED STATES
View details

Xianghua Luo

Professor

University of Minnesota

UNITED STATES
View details

Marina N Sharifi

Assistant Professor

University of Wisconsin-Madison

UNITED STATES
View details

Manish Kohli

Professor

Huntsman Cancer Institute

UNITED STATES
View details

Emmanuel Stylianos Antonarakis

Professor of Medicine, Associate Director for Translation

-

UNITED STATES
View details

Mitchell G Lawrence

-

AUSTRALIA
View details

Emmanuel S. Antonarakis

-

UNITED STATES
View details

Carly Miller

University of Minnesota

UNITED STATES
View details

Jeffrey S Miller

University of Minnesota System

UNITED STATES
View details

Felix Y. Feng

University of California

UNITED STATES
View details

Mukesh Pandey

Professor of Radiology

Mayo Clinic

UNITED STATES
View details

Luke Hoeppner

Faculty, Associate Professor

University of Minnesota

UNITED STATES
View details

Atish Choudhury

Dana-Farber Cancer Institute

UNITED STATES
View details

Erika Heninger

University of Wisconsin-Madison

UNITED STATES
View details

Douglas Yee

Professor

University of Minnesota

UNITED STATES
View details

Peter S. Nelson

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

TINGYOU WANG

Research Assistant Professor

Northwestern University Feinberg School of Medicine

UNITED STATES
View details

Sk. Kayum Alam

Researchers, Research Professional 5

University of Minnesota

UNITED STATES
View details

Nicholas Zorko

Assistant Professor

University of Minnesota

UNITED STATES
View details

Neeraj Agarwal

Faculty Member

Dana-Farber Cancer Institute

UNITED STATES
View details

Daniel P. Petrylak

-

UNITED STATES
View details

Sabine Karam

Associate Professor of Medicine

University of Minnesota

UNITED STATES
View details

Justin M. Drake

University of Minnesota

UNITED STATES
View details

Rana R. McKay

University of California, San Diego

UNITED STATES
View details

Dave Hoon

Principal Investigator

The Lundquist Institute

UNITED STATES
View details

Ruping Sun

Assistant Professor

University of Minnesota

UNITED STATES
View details

R. Stephanie Huang

Faculty, Professor

University of Minnesota

UNITED STATES
View details